Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, shares the primary results of the Phase III DESTINY-Breast02 (NCT03523585) trial of trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice in the third-line setting or more in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1). The primary endpoint was progression-free survival (PFS). A significant improvement in PFS was observed of almost a year. However, following the results of the results of the Phase III DESTINY-Breast03 (NCT03529110) and an approval of T-DXd in the second-line setting, this patient population is likely to have been treated with T-DXd in the second-line as opposed to later lines of treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
